MedTrace Logo

Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2

NCT03209869 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2022-09-13

No results posted yet for this study

Summary

Subjects with relapsed or refractory neuroblastoma and osteosarcoma will receive ex-vivo expanded and activated natural killer (NK) cells from a haploidentical donor in conjunction with the immunocytokine, hu14.18-IL2.

Conditions

Interventions

BIOLOGICAL

Ex vivo Expanded and Activated Haploidentical Donor NK Cells

Haploidentical donor NK cells that are expanded and activated under current GMP conditions using K562-mbIL15-41BBL.

BIOLOGICAL

Hu14.18-IL2

The immunocytokine, hu14.18-IL2, is a fusion protein comprised of one molecule of the anti-GD2 humanized monoclonal antibody, hu14.18, fused to two molecules of the cytokine, interleukin-2.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Solving Kids' Cancer

    collaborator OTHER

  • Midwest Athletes Against Childhood Cancer, Inc. (MACC Fund)

    collaborator UNKNOWN

  • Wade's Army

    collaborator UNKNOWN

  • The Catherine Elizabeth Blair Memorial Foundation / GWCF

    collaborator UNKNOWN

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Ken DeSantes, MD · University of Wisconsin, Madison

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
7 Months
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-12
Primary Completion
2022-09-07
Completion
2022-09-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03209869 on ClinicalTrials.gov